VERU Earnings Prediction
The chart below shows how VERU performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VERU sees a +2.30% change in stock price 10 days leading up to the earnings, and a +0.72% change 10 days following the report. On the earnings day itself, the stock moves by -2.50%. This data can give you a slight idea of what to expect for the next quarter's release.
VERU Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.95M
18.34%
-4.39%
Gross Margin
33.84%
-8.12%
106.34%
Operating Margin
-279.44%
-49.42%
16.86%
Net Margin
-277.42%
-25.98%
14.42%
EPS
-0.07
-50.00%
-0.00%
No Data Available
VERU Earnings Analysis
Veru Inc. Corporation (VERU.O) Earnings Conference Call
Positive
Veru Inc. is focused on developing innovative medicines for weight loss, oncology, and acute respiratory distress syndrome, highlighting a diverse drug development pipeline.
Veru Inc.'s drug development pipeline includes late-stage novel oral small molecules like Enobosarm and Sepisabulin, showing a commitment to addressing unmet medical needs across various therapeutic areas.
Enobosarm in combination with semaglutide is being developed to preserve muscle mass and augment fat loss for higher-quality weight loss.
Enobosarm aims to prevent the loss of muscle mass caused by GLP-1 receptor agonist drugs, which accelerates frailty and muscle weakness in older patients. The drug has the potential to address a critical need in preserving muscle mass during weight loss treatment.
Enobosarm's Phase IIb clinical trials to assess muscle preservation and fat reduction in overweight or obese patients show promising results.
The Phase IIb quality clinical trial is designed to evaluate the optimal dose of Enobosarm in combination with semaglutide, targeting lean body mass preservation and reduction of fat mass for improved body composition.
Veru Inc. has sufficient financial resources to complete the ongoing clinical trials and provide results until 2025.
The company reported a cash balance of $29.2 million at the end of June 2024, ensuring the completion of Phase IIb quality clinical trial and the Phase IIb extension clinical trial.
Clinical data from previous studies supports Enobosarm's potential to preserve total lean body mass and reduce fat mass for precision weight loss.
Enobosarm has demonstrated tissue selectivity and safety in clinical trials, showcasing its ability to favorably impact body composition and potentially achieve higher-quality weight loss in patients who are overweight or obese.
Negative
- Decrease in net revenues for the U.S. prescription business compared to the prior year's third quarter, with sales dropping from $863,000 to $552,000.
- Gross profit decreased to 34% of net revenues compared to 37% in the previous quarter, due to a change in sales mix.
- Net loss of $11 million in the third quarter, indicating financial challenges in profitability.
- Cash used for operating activities increased to $5.6 million for the quarter, reflecting higher operational expenses.
- Reduction in research and development costs to $4.9 million from $8.8 million in the previous quarter, potentially impacting future drug development initiatives.
VERU FAQs
How does VERU typically perform around its earnings report dates?
Is Veru Inc. (VERU) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VERU Earning Call Sentiment
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VERU.O
-2.82%Positive
The earnings call reflects mixed signals: improved financial health with reduced operating expenses and losses, but declining revenues and gross margins. The Q&A section highlights some uncertainty in management's responses, particularly regarding future phases of the drug pipeline. The lack of clarity on top-line data and potential partnerships adds to investor uncertainty. Despite a strong market opportunity in obesity drugs, the absence of clear guidance and declining U.S. prescription revenues tempers optimism. Without a market cap, the stock's sensitivity is unclear, leading to a neutral prediction.
